ADMA Biologics (ADMA) Misses Q2 EPS by 1c

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $121.98 million versus the consensus estimate of $124.13 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Lockheed Martin wins $8.4B missile contract modification
• Cerebras Q1 EPS miss sends shares down 9% after-hours